Results from two small clinical trials have shown that intradermal injection of the immune system–boosting agent CpG-B after surgery can reduce the recurrence risk for stage I/II melanoma. The study was presented at the 2015 International Cancer Immunotherapy Conference (abstract A050)
MRV Research
Genetic Tests Show How Sunlight Turns Moles into Melanoma
Researchers have found a new way to tell if a suspicious-looking mole is about to turn malignant by looking at its genetic changes.
Melanoma’s genetic trajectories are charted in new study
An international team of scientists led by UC San Francisco researchers has mapped out the genetic trajectories taken by melanoma as it evolves from early skin lesions, known as precursors, to malignant skin cancer, which can be lethal when it invades other tissues in the body.
Survival Benefit in Metastatic Melanoma Grows Larger in COMBI-v Update
Combined BRAF and MEK inhibition was superior to BRAF inhibition alone in unresectable metastatic melanoma, according to the updated survival analysis of the large randomized COMBI-v trial.1 These findings were reported at the 2015 European Cancer Congress recently held in Vienna, Austria.